-
1
-
-
0036499084
-
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival
-
Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1288-1294
-
-
Howard, O.M.1
Gribben, J.G.2
Neuberg, D.S.3
-
2
-
-
20144376591
-
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
-
Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1984-1992
-
-
Lenz, G.1
Dreyling, M.2
Hoster, E.3
-
3
-
-
77954334194
-
Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
-
Romaguera JE, Fayad LE, Feng L et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200-208.
-
(2010)
Br J Haematol
, vol.150
, pp. 200-208
-
-
Romaguera, J.E.1
Fayad, L.E.2
Feng, L.3
-
4
-
-
0033970534
-
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997
-
Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
-
(2000)
Histopathology
, vol.36
, pp. 69-86
-
-
Harris, N.L.1
Jaffe, E.S.2
Diebold, J.3
-
5
-
-
27244452464
-
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
-
Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7013-7023
-
-
Romaguera, J.E.1
Fayad, L.2
Rodriguez, M.A.3
-
6
-
-
33845382806
-
Nonparametric estimation from incomplete observations
-
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.1
Meier, P.2
-
7
-
-
0000336139
-
Regression models and life tables
-
Cox D. Regression models and life tables. J R Stat Assoc 1972; 34: 187-220.
-
(1972)
J R Stat Assoc
, vol.34
, pp. 187-220
-
-
Cox, D.1
-
8
-
-
0027444652
-
The International Non-Hodgkin's Lymphoma Prognostic Factors Project
-
A predictive model for aggressive non-Hodgkin's lymphoma
-
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
-
(1993)
N Engl J Med
, vol.329
, pp. 987-994
-
-
-
9
-
-
38349104577
-
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
-
Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
-
(2008)
Blood
, vol.111
, pp. 558-565
-
-
Hoster, E.1
Dreyling, M.2
Klapper, W.3
-
10
-
-
84872054301
-
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
-
Delarue R, Haioun C, Ribrag V et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121: 48-53.
-
(2013)
Blood
, vol.121
, pp. 48-53
-
-
Delarue, R.1
Haioun, C.2
Ribrag, V.3
-
11
-
-
84863822702
-
Nordic MCL2 trial update: six-year followup after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur
-
Geisler CH, Kolstad A, Laurell A et al. Nordic MCL2 trial update: six-year followup after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
-
(2012)
Br J Haematol
, vol.158
, pp. 355-362
-
-
Geisler, C.H.1
Kolstad, A.2
Laurell, A.3
-
12
-
-
53449089095
-
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
-
Geisler CH, Kolstad A, Laurell A et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
-
(2008)
Blood
, vol.112
, pp. 2687-2693
-
-
Geisler, C.H.1
Kolstad, A.2
Laurell, A.3
-
13
-
-
84855796484
-
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
-
Merli F, Luminari S, Ilariucci F et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346-353.
-
(2012)
Br J Haematol
, vol.156
, pp. 346-353
-
-
Merli, F.1
Luminari, S.2
Ilariucci, F.3
-
14
-
-
84857748460
-
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
-
Lacasce AS, Vandergrift JL, Rodriguez MA et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119(9): 2093-2099.
-
(2012)
Blood
, vol.119
, Issue.9
, pp. 2093-2099
-
-
Lacasce, A.S.1
Vandergrift, J.L.2
Rodriguez, M.A.3
-
15
-
-
85014234123
-
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study
-
Lefrere F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587-593.
-
(2002)
Leukemia
, vol.16
, pp. 587-593
-
-
Lefrere, F.1
Delmer, A.2
Suzan, F.3
-
16
-
-
78951495411
-
Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net)
-
Hermine O, Hoster E, Walewski J et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annu Meeting Abstr 2010; 116: 110.
-
(2010)
ASH Annu Meeting Abstr
, vol.116
, pp. 110
-
-
Hermine, O.1
Hoster, E.2
Walewski, J.3
-
17
-
-
84864715966
-
Treatment of older patients with mantle-cell lymphoma
-
Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
-
(2012)
N Engl J Med
, vol.367
, pp. 520-531
-
-
Kluin-Nelemans, H.C.1
Hoster, E.2
Hermine, O.3
-
18
-
-
79959722615
-
An international phase II trial of singleagent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
-
Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of singleagent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
-
(2011)
Ann Oncol
, vol.22
, pp. 1622-1627
-
-
Witzig, T.E.1
Vose, J.M.2
Zinzani, P.L.3
-
19
-
-
79953182631
-
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
-
Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361-368.
-
(2011)
Lancet Oncol
, vol.12
, pp. 361-368
-
-
Ansell, S.M.1
Tang, H.2
Kurtin, P.J.3
-
20
-
-
84860430028
-
The Bruton's tyrosine kinase inhibitor PCI- 32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial
-
Wang L, Martin P, Blum KA et al. The Bruton's tyrosine kinase inhibitor PCI- 32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. ASH Annu Meeting Abstr 2011; 118: 442-.
-
(2011)
ASH Annu Meeting Abstr
, vol.118
, pp. 442
-
-
Wang, L.1
Martin, P.2
Blum, K.A.3
|